Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz

Drug Metabolism Letters

Volumn 2, Issue 4, 2008, Pages 269-274

  Esteban, Javier ^a   de la Cruz Pellín, María ^a   Gimeno, Carmen ^b   Barril, José ^a   Giménez, Jesús ^a   Mora, Eva ^b   Garcia Pérez, Adolfo G ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b Unidad de Conductas Adictivas   (Spain)

Author keywords

CYP2B6; CYP3A4; Efavirenz; Hepatitis C Virus; Methadone; Nevirapine

Indexed keywords

CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; EFAVIRENZ; METHADONE; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; N DEMETHYLASE; NARCOTIC AGENT; S MEPHENYTOIN N DEMETHYLASE; S-MEPHENYTOIN N-DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG POTENTIATION; ENANTIOMER; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUBSTANCE ABUSE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG INTERACTION; ENZYME INDUCTION; FOLLOW UP; METABOLISM; STEREOISOMERISM;

HEPATITIS C VIRUS;

ADULT; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INDUCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; METHADONE; NARCOTICS; NEVIRAPINE; OXIDOREDUCTASES, N-DEMETHYLATING; STEREOISOMERISM;

EID: 65249095266     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231208786734067     Document Type: Article

References (33)

1. Kristensen, K.; Christensen, C.B.; Christrup, L.L. Life. Sci., 1995, 56, L45-L50.
2. Gutstein, H.B.; Akil, H. In Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. Ed.; McGraw-Hill Companies: New York, 2001, pp. 569-620.
3. Esteban, J.; Gimeno, C.; Aragones, A.; Barril, J.; Pellin, M.C. Med. Clin., 2003, 120, 765-7.
4. Esteban, J.; Gimeno, C.; Barril, J.; Aragones, A.; Climent, J.M.; Pellin, M.C. Drug Alcohol Depend., 2003, 70, 193-200.
5. Portilla, J.; Esteban, J.; Llinares, R.; Belda, J.; Sanchez-Paya, J.; Isabel, M.M.; de Estudio, P. Med. Clin., 2001, 116, 330-2.
6. Eap, C.B.; Buclin, T.; Baumann, P. Clin. Pharmacokinet., 2002, 41, 1153-93.
7. Esteban, J.; Pellin, M.C.; Gimeno, C.; Barril, J.; Toxicol. Lett., 2004, 151, 243-9.
8. Iribarne, C.; Berthou, F.; Baird, S.; Dreano, Y.; Picart, D.; Bail, J.P.; Beaune, P.; Menez, J.F. Chem. Res. Toxicol., 1996, 9, 365-73.
9. Moody, D.E.; Alburges, M.E.; Parker, R.J.; Collins, J.M.; Strong, J.M.; Drug Metab. Dispos., 1997, 25, 1347-53.
10. Gerber, J.G.; Rhodes, R.J.; Gal, J. Chirality, 2004, 16, 36-44.
11. Wang, J.S.; DeVane, C.L. Drug Metab. Dispos., 2003, 31, 742-7.
12. Foster, D.J.; Somogyi, A.A.; Bochner, F. Br. J. Clin. Pharmacol., 1999, 47, 403-12.
13. Crettol, S.; Deglon, J.J.; Besson, J.; Croquette-Krokkar, M.; Gothuey, I.; Hammig, R.; Monnat, M.; Huttemann, H.; Baumann, P.; Eap, C.B. Clin. Pharmacol. Ther., 2005, 78, 593-604.
14. Kharasch, E.D.; Hoffer, C.; Whittington. D.; Sheffels, P. Clin. Pharmacol. Ther., 2004, 76, 250-69.
15. Back, D.; Gibbons, S.; Khoo, S. JAIDS, 2003, 34, S8-S14.
16. Begre, S.; von Bardeleben, U.; Ladewig, D.; Jaquet-Rochat, S.; Cosendai-Savary, L.; Golay, K.P.; Kosel, M.; Baumann, P.; Eap, C.B. J. Clin. Psychopharmacol., 2002, 22, 211-5.
17. Eap, C.B.; Broly, F.; Mino, A.; Hammig, R.; Deglon, J.J.; Uehlinger, C.; Meili, D.; Chevalley, A.F.; Bertschy, G.; Zullino, D.; Kosel, M.; Preisig, M.; Baumann, P. J. Clin. Psychopharmacol., 2001, 21, 229-34.
18. Crettol, S.; Deglon, J.J.; Besson, J.; Croquette-Krokar, M.; Hammig, R.; Gothuey, I.; Monnat, M.; Eap, C.B. Clin. Pharmacol. Ther., 2006, 80, 668-81.
19. Altice, F.L.; Friedland, G.H.; Cooney, E.L. AIDS, 1999, 13, 957-62.
20. Clarke, S.M.; Mulcahy, F.M.; Tjia, J.; Reynolds, H.E.; Gibbons, S.E.; Barry, M.G.; Back, D.J. Br. J. Clin. Pharmacol., 2001, 51, 213-7.
21. Clarke, S.M.; Mulcahy, F.M.; Tjia, J.; Reynolds, H.E.; Gibbons, S.E.; Barry, M.G.; Back, D.J. Clin. Infect. Dis., 2001, 33, 1595-7.
22. Marzolini, C.; Troillet, N.; Telenti, A.; Baumann, P.; Decosterd, L.A.; Eap, C.B. AIDS, 2000, 14, 1291-2.
23. Otero, M.J.; Fuertes, A.; Sanchez, R.; Luna, G. AIDS, 1999, 13, 1004-5.
24. Stocker, H.; Kruse, G.; Kreckel, P.; Herzmann, C.; Arasteh, K.; Claus, J.; Jessen, H.; Cordes, C.; Hintsche, B.; Schlote, F.; Schneider, L.; Kurowski, M. Antimicrob. Agents Chemother., 2004, 48, 4148-53.
25. Pinzani, V.; Faucherre V.; Peyriere H.; Blayac, J.P. Ann. Pharmacother., 2000, 34, 405-7.
26. Pham-Huy, C.; ChikhiChorfi, N.; Galons, H.; Sadeg, N.; Laqueille, X.; Aymard, N.; Massicot, F.; Warnet, J.M.; Claude, J.R. J. Chromatogr. B, 1997, 700, 155-63.
27. Handelsman, L. Cochrane, K.J.; Aronson, M.J.; Ness, R.; Rubinstein, K.J.; Kanof, P.D. Am. J. Drug Alcohol Abuse, 1987, 13, 293-308.
28. Dyer, K.R.; Foster, D.J.R.; White, J.M.; Somogyi, A.A.; Menelaou, A.; Bochner, F. Clin. Pharmacol. Ther., 1999, 65, 685-94.
29. Okruhlica, L.; Klempova, D. Heroin Add. Rel. Clin. Probl., 2000, 2, 57-8.
30. Maxwell, S.; Shinderman, M.; Miner, A.; Bennet, A. Heroin Add. Rel. Clin. Probl., 2002, 4, 5-10.
31. Burger, D.; van der Heiden, I.; la Porte, C.; van der Ende, M.; Groeneveld, P.; Richter, C.; Koopmans, P.; Kroon, F.; Sprenger, H.; Lindemans, J.; Schenk, P.; van Schaik, R. Br. J. Clin. Pharmacol., 2006, 61, 148-54.
32. Rendon, A.L.; Nunez, M.; Jimenez-Nacher, I.; de Requena, D.G.; Gonzalez-Lahoz, J.; Soriano, V. HIV Med., 2005, 6, 360-5.
33. von Moltke, L.L.; Greenblatt, D.J.; Granda, B.W.; Giancarlo, G.M.; Duan, S.X.; Daily, J.P.; Harmatz, J.S.; Shader, R.I. J. Clin. Pharmacol., 2001, 41, 85-91.